Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00499720|
Expanded Access Status : Approved for marketing
First Posted : July 11, 2007
Last Update Posted : August 2, 2011
|Condition or disease||Intervention/treatment|
|Cystic Fibrosis Pseudomonas Aeruginosa Airway Infection||Drug: Aztreonam Lysine for Inhalation|
|Study Type :||Expanded Access|
|Official Title:||Expanded Access Program for Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection Who Have Limited Treatment Options and Are at Risk for Disease Progression|
- Drug: Aztreonam Lysine for Inhalation
75 mg three times a day via inhalation for 28 days followed by 28 days off drug.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00499720
Show 65 Study Locations